Medical and Molecular Microbiology, Faculty of Science and Medicine, University of Fribourg, Fribourg, Switzerland.
Department of Food Hygiene and Control, Faculty of Veterinary Medicine, South Valley University, Qena, Egypt.
Antimicrob Agents Chemother. 2023 May 17;67(5):e0007823. doi: 10.1128/aac.00078-23. Epub 2023 Apr 11.
The activity of imipenem-relebactam, meropenem-vaborbactam, ceftazidime-avibactam, and cefiderocol was evaluated against both clinical and isogenic enterobacterial isolates producing carbapenemases of the SME, NmcA, FRI, and IMI types. Ceftazidime-avibactam and meropenem-vaborbactam showed the highest activity against all tested isolates; imipenem-relebactam showed only moderate activity. All isolates remained susceptible to cefiderocol. Furthermore, avibactam and vaborbactam have greater inhibitory activity than relebactam against the tested carbapenemases. Overall, ceftazidime-avibactam, meropenem-vaborbactam, and cefiderocol were the most effective therapeutic options for treating infections caused by the tested minor carbapenemase producers.
研究评估了亚胺培南-雷巴坦、美罗培南-沃巴坦、头孢他啶-阿维巴坦和头孢地尔在针对产 SME、NmcA、FRI 和 IMI 型碳青霉烯酶的临床和同源肠杆菌分离株中的活性。头孢他啶-阿维巴坦和美罗培南-沃巴坦对所有测试分离株显示出最高的活性；亚胺培南-雷巴坦显示出中等活性。所有分离株对头孢地尔仍保持敏感。此外，阿维巴坦和沃巴坦对测试的碳青霉烯酶的抑制活性大于雷巴坦。总体而言，头孢他啶-阿维巴坦、美罗培南-沃巴坦和头孢地尔是治疗测试的低水平碳青霉烯酶产生菌引起的感染的最有效治疗选择。
